Migraine headache is routinely managed using medications that abort attacks as they occur. An alternative approach to migraine management is based on prophylactic medications that reduce attack frequency. One approach has been based on local intramuscular injections of Botulinum Toxin Type A (BTX-A). Here, we explored for neurological markers that might distinguish migraine patients who benefit from BTX-A treatment (100 units divided into 21 injections sites across pericranial and neck muscles). Responders and non-responders to BTX-A treatment were compared prospectively (n = 27) and retrospectively (n = 36) for a host of neurological symptoms associated with their migraine. Data pooled from all 63 patients are summarized below. The number of migraine days per month dropped from 16.0 ± 1.7 before BTX-A to 0.8 ± 0.3 after BTX-A (down 95.3 ± 1.0%) in 39 responders, and remained unchanged (11.3 ± 1.9 vs. 11.7 ± 1.8) in 24 non-responders. The prevalence of aura, photophobia, phonophobia, osmophobia, nausea, and throbbing was similar between responders and non-responders. However, the two groups offered different accounts of their pain. Among non-responders, 92% described a buildup of pressure inside their head (exploding headache). Among responders, 74% perceived their head to be crushed, clamped or stubbed by external forces (imploding headache), and 13% attested to an eye-popping pain (ocular headache). The finding that exploding headache was impervious to extracranial BTX-A injections is consistent with the prevailing view that migraine pain is mediated by intracranial innervation. The amenability of imploding and ocular headaches to BTX-A treatment suggests that these types of migraine pain involve extracranial innervation as well. Ó
Introduction
Migraine is a throbbing headache routinely managed using medications that abort attacks as they occur. An alternative approach to migraine management is based on prophylactic medications that reduce attack frequency. One approach has been based on local intramuscular injections of Botulinum Toxin Type A (BTX-A), a neurotoxin that causes transient muscle paralysis (Simpson, 1981; Black and Dolly, 1986a,b; Lawrence and Dolly, 2002a,b; Dolly, 2003; Foran et al., 2003) . Clinical studies on the efficacy of BTX-A treatment for migraine prophylaxis have generally failed to demonstrate its superiority over placebo using analysis of pooled data from all participants (Binder et al., 2000; Silberstein et al., 2000; Evers et al., 2004; Ondo et al., 2004; Tepper et al., 2004; Dodick et al., 2005) . However, many clinicians are well aware that in some patients BTX-A 
